Compass Pathways completa solicitud de aprobación ante FDA para COMP360 contra depresión resistente al tratamiento
- Compass Pathways completó la solicitud de autorización a la FDA para COMP360, psilocibina sintética para la depresión resistente al tratamiento.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109020822) on November 09, 2026, and is solely responsible for the information contained therein.